KR900002804A - 세포독성 약물 결합체 및 이의 제조방법 - Google Patents

세포독성 약물 결합체 및 이의 제조방법 Download PDF

Info

Publication number
KR900002804A
KR900002804A KR1019890011217A KR890011217A KR900002804A KR 900002804 A KR900002804 A KR 900002804A KR 1019890011217 A KR1019890011217 A KR 1019890011217A KR 890011217 A KR890011217 A KR 890011217A KR 900002804 A KR900002804 A KR 900002804A
Authority
KR
South Korea
Prior art keywords
formula
phenyl
antibody
carbonyl
bond
Prior art date
Application number
KR1019890011217A
Other languages
English (en)
Inventor
조셉 컬리난 조오지
코울맨 라구자 버네트
레오나드 스코트 윌리암
Original Assignee
메리 앤 터커
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메리 앤 터커, 일라이 릴리 앤드 캄파니 filed Critical 메리 앤 터커
Publication of KR900002804A publication Critical patent/KR900002804A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

내용 없음

Description

세포독성 약물 결합체 및 이의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 일반식(Ⅰ)의 세포독성 약물 결합체.
    상기식에서, Ab는 목적하지 않는 세포와 결합한 항원을 인지하는 생리학적으로 허용되는 항체 또는 이의 항원-인지 단편이고, m은 1 내지 약 10의 정수이며, Z는 수소 또는 C1-C3비측쇄 알킬이고, X는 결합, C1-C4알킬렌, C2-C4알케닐렌 또는 아미노-C1-C4알킬렌이며, Y는 결합, 카보닐, -O-, -S- 또는 설포닐이고, 단, X가 아미노알킬렌일 경우, Y는 카보닐 또는 설포닐이고, X가 결합인 경우, Y는 결합 또는 카보닐이며, Ar은 피롤릴, m-페닐 또는 p-페닐(여기에서, 페닐그룹은 브로모, 클로로, 플루오로, 메톡시, 니트로 또는 C1-C3알킬로 일- 또는 이치환될 수 있다)이고, Ⅴ는 일반식(Ⅱ)의 빈카 약물이다.
    (여기에서, R은 H, CH3또는 CHO이고 ; R2및 R3가 단독으로 존재할 경우, R3는 H이고, R1및 R2중의 하나는 에틸이고 다른 하나는 H 또는 OH이며 ; R2및 R3가 이들이 결합하고 있는 탄소와 함께 존재할 경우, 이들은 R1이 에틸인 옥시란 환을 형성하고 ; R4는 H, (C1-C3알킬)-CO 또는 클로로 치환된 (C1-C3알킬)-CO이다.)
  2. 제 1 항에 있어서, 항체 또는 이의 단편이 암세포를 인지하는 결합체.
  3. 제 1 항 또는 2항에 있어서, 항체가 모노클로날 또는 키메릭 항체이거나 이의 항원-인지 단편인 결합체.
  4. 제 1 항 내지 3항중 어느 한 항에 있어서, Ar이 페닐, 일치환된 페닐 또는 피롤릴인 결합체.
  5. 제 1 항에 있어서, L/IC2와 4-데스아세틸-23-데스메톡시-빈블라스틴, 카보닐-4-벤질리덴하이드라지드의 결합체.
  6. 활성화제로서 제 1 항 내지 5항 중 어느 한 항에서 청구한 결합체를, 하나 이상의 약제학적으로 허용되는 담체 또는 희석제와 결합된 형태로 함유하는 약제학적 제제.
  7. 하기 일반식(A)의 화합물.
    상기식에서, R는 하이드록시, 산-활성화 그룹, 염을 완성시키는 부분, 또는 산-보호 그룹이고, X, Y, Ar 및 V는 제1항에서 정의한 바와 같다.
  8. 제 7 항에 있어서, Ar이 피롤릴 또는 p-페닐인 화합물.
  9. (A) 제 1 항에서 정의한 바와 같은 일반식(Ab)의 생리학적으로 허용되는 항체 또는 이의 항원-인지 단편을 일반식(A)의 중간물질과 반응시키거나, (B)일반식 (B)의 변형된 항체를 일반식(C)의 동량의 하이드라지드와 반응시킴을 특징으로 하여, 제 1 항 내지 5항중 어느 한 항에서 청구한 결합체를 제조하는 방법.
    H2N-NH-V (C)
    상기식에서, R5는 하이드록시, 산-활성화 그룹, 염을 완성시키는 부분 또는 산-보호 그룹이고, Ab, X, Y, Ar, Z, m 및 V는 제 1 항에서 정의한 바와 같다.
  10. 제 9 항의 방법으로 제조된 일반식(Ⅰ)의 결합체.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890011217A 1988-08-08 1989-08-07 세포독성 약물 결합체 및 이의 제조방법 KR900002804A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/230,084 US5006652A (en) 1988-08-08 1988-08-08 Intermediates for antibody-vinca drug conjugates
US230,084 1988-08-08

Publications (1)

Publication Number Publication Date
KR900002804A true KR900002804A (ko) 1990-03-23

Family

ID=22863896

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890011217A KR900002804A (ko) 1988-08-08 1989-08-07 세포독성 약물 결합체 및 이의 제조방법

Country Status (15)

Country Link
US (1) US5006652A (ko)
EP (1) EP0354728A3 (ko)
JP (1) JPH02131499A (ko)
KR (1) KR900002804A (ko)
CN (1) CN1040205A (ko)
AR (1) AR245368A1 (ko)
AU (1) AU619329B2 (ko)
DK (1) DK382989A (ko)
HU (1) HU206377B (ko)
IL (1) IL91182A0 (ko)
MX (1) MX164971B (ko)
NZ (1) NZ230200A (ko)
PH (1) PH27351A (ko)
PT (1) PT91372A (ko)
ZA (1) ZA895908B (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
US5272253A (en) * 1991-07-01 1993-12-21 Eli Lilly And Company Cluster conjugates of drugs with antibodies
ES2049656B1 (es) * 1992-10-08 1994-11-16 Lilly Co Eli Grupos de conjugados de farmacos con anticuerpos.
GR1001459B (el) * 1992-10-08 1993-12-30 Lilly Co Eli Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
AU2002217980A1 (en) 2000-12-01 2002-06-11 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide
DE60231868D1 (de) 2001-04-24 2009-05-20 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
WO2003097647A1 (en) * 2002-05-15 2003-11-27 Endocyte, Inc. Vitamin-mitomycin conjugates
DK1592457T3 (da) 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
US8044200B2 (en) * 2005-03-16 2011-10-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
AU2006279304A1 (en) * 2005-08-19 2007-02-22 Endocyte, Inc. Multi-drug ligand conjugates
EP2382995A3 (en) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
WO2008101231A2 (en) * 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
WO2008112873A2 (en) * 2007-03-14 2008-09-18 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
CN104383553A (zh) * 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
EP2209374B1 (en) 2007-10-25 2014-12-03 Endocyte, Inc. Tubulysins and processes for preparing
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
BR112015008365A2 (pt) 2012-10-16 2017-07-04 Endocyte Inc composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
PT2968440T (pt) 2013-03-15 2019-07-31 Zymeworks Inc Compostos citotóxicos e antimitóticos e métodos de utilização dos mesmos
EP3086815B1 (en) 2013-12-27 2022-02-09 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
EP3194421B1 (en) 2014-09-17 2021-11-03 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
FI820020L (fi) * 1981-01-12 1982-07-13 Lilly Industries Ltd Immunoglobulinkonjugater
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
GB2137210B (en) * 1983-03-30 1986-11-19 Lilly Industries Ltd Immunoglobulin conjugates
EP0124502B1 (fr) * 1983-04-29 1991-06-12 OMNICHEM Société anonyme Nouveaux conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques contenant ces conjugués
LU86157A1 (fr) * 1985-11-12 1987-06-26 Omnichem Sa Nouveau procede de fabrication de conjugues de la vinblastine et de ses derives
US4675400A (en) * 1985-06-17 1987-06-23 Eli Lilly And Company Bifunctional derivatives of 4-desacetyl indole-dihydroindole alkaloids
EP0232693A3 (fr) * 1985-12-16 1988-04-06 La Region Wallonne Conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques les contenant
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
IL82579A0 (en) * 1986-05-27 1987-11-30 Lilly Co Eli Immunoglobulin conjugates
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
FR2610198B1 (fr) * 1987-02-03 1990-06-15 Ire Celltarg Sa Conjugues d'hydrazide d'alcaloide de vinca lie a une immunoglobuline, procede de preparation et compositions pharmaceutiques en comprenant
IL89043A0 (en) * 1988-01-27 1989-08-15 Lilly Co Eli Antibody conjugates

Also Published As

Publication number Publication date
HUT50488A (en) 1990-02-28
EP0354728A2 (en) 1990-02-14
AR245368A1 (es) 1994-01-31
DK382989A (da) 1990-02-09
AU619329B2 (en) 1992-01-23
IL91182A0 (en) 1990-03-19
EP0354728A3 (en) 1991-04-10
ZA895908B (en) 1991-04-24
AU3933989A (en) 1990-02-08
MX164971B (es) 1992-10-09
PT91372A (pt) 1990-03-08
JPH02131499A (ja) 1990-05-21
US5006652A (en) 1991-04-09
NZ230200A (en) 1991-11-26
DK382989D0 (da) 1989-08-04
CN1040205A (zh) 1990-03-07
PH27351A (en) 1993-06-21
HU206377B (en) 1992-10-28

Similar Documents

Publication Publication Date Title
KR900002804A (ko) 세포독성 약물 결합체 및 이의 제조방법
US5157104A (en) Trichothecene conjugates
KR900002803A (ko) 세포독성 약물 결합체
US5141736A (en) Bispecific monoclonal antibody, its production and use
KR890007724A (ko) 약물-모노클로날 항체 결합체
CA2495795A1 (en) Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
RU98110565A (ru) Новые соединения и их композиции, обладающие противовоспалительной и противотромботической активностями
EA010508B1 (ru) Способ прицельного воздействия на определенные популяции клеток с помощью конъюгатов из майтансиноида и агента клеточного связывания, соединенных через нерасщепляемый линкер, конъюгаты и способы получения таких конъюгатов
RU95112841A (ru) Полимерный конъюгат, способ его получения, производная 20-0-ациламинокамптотецина и способ ее получения, фармацевтическая композиция
CA2494049A1 (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
FI802278A (fi) Antitumoer-proteinhybrid och foerfarande foer framstaellning daerav
PT1242401E (pt) Agentes citotóxicos compreendendo taxanos e o seu uso terapêutico
KR920700205A (ko) 트리-아자 마크로싸이클 화합물과 이들의 금속착화합물
KR840007412A (ko) 벤조-헤테로 고리 화합물의 제조방법
KR870011132A (ko) 면역글로불린 결합체
CA2016584C (en) Anthracycline conjugates having a novel linker and methods for their production
US5021571A (en) Cyclohexyl EDTA monoanhydride
KR920021141A (ko) 갈륨 화합물
HK1013420A1 (en) Molecule labelling using 2-hydraninopyridine derivatives
ES2104682T3 (es) Fluor-compuestos.
KR840006985A (ko) N-치환플라본-8-카르복사미드유도체 및 그 제조방법
GB1515019A (en) Substituted imidazolidines and pharmaceutical uses thereo
KR830004220A (ko) 약리적 활성 펩티드
CZ293228B6 (cs) Substituovaný disulfid, jeho konjugát s nosičem a způsoby přípravy tohoto disulfidu a konjugátu
KR830004219A (ko) 약리적 활성 펩티드

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid